Details of the Drug Reposition

General Information of This Drug (ID: DMUAXS5)

Drug Name
FP-1039   DMUAXS5
Synonyms
FPT-039; HGS-1036; Modified growth factor receptor (cancer), FivePrime Therapeutics; FGFR-1c antagonist (protein fusion/iv,cancer), FivePrime Therapeutics; FGFR-1c antagonist (protein fusion/iv, cancer), FivePrime Therapeutics/ Human Genome Sciences

Information on Drug Reposition of This Drug

Molecular Interaction Atlas (MIA)
1 Phase 2 Indication(s)
Indication Name Indication ID ICD-11 Status REF
Endometrial cancer DISW0LMR 2C76 Phase 2 [1]
------------------------------------------------------------------------------------
1 Phase 1b Indication(s)
Indication Name Indication ID ICD-11 Status REF
Solid tumour/cancer DISZR48F 2A00-2F9Z Phase 1b [2]
------------------------------------------------------------------------------------

References

1 ClinicalTrials.gov (NCT01244438) Study of FP-1039 in Subjects With Endometrial Cancers. U.S. National Institutes of Health.
2 Clinical pipeline report, company report or official report of Five Prime Therapeutics.